euro adhoc: Intercell AG / other / Intercell starts pivotal Phase III clinical trials of Japanese Encephalitis Vaccine
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 19.09.2005 Vienna, Austria, September 19, 2005 - Intercell AG (VSE, "ICLL") announced today the start of global multi-center Phase III clinical trials of its Japanese Encephalitis vaccine, IC51. ...